Shots: The sBLA submission is based on P-III POLYP 1 & 2 studies assessing Xolair (SC) vs PBO in 138 & 127 patients with CRSwNP with inadequate response to intranasal […]readmore
Tags : Novartis
1. Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders Published: Dec 05, 2019 | Tags: Sage Therapeutics, Reports, Results, SAGE-217, P-III, MOUNTAIN Study, Major […]readmore
Shots: The P-III PALLADIUM study involves assessing of QMF149 [indacaterol acetate + mometasone furoate (IND/MF)] vs mometasone furoate (MF) as monothx. in 2,216 asthma patients with medium or high dose […]readmore
Shots: Novartis reports that it has 60 projects in P-II with expected 10+ products to enter in P-III study in 2020 & 2021 while 90% of them are first-in-class or […]readmore
Shots: Novartis signs a strategic agreement with Novartis to reimagine its manufacturing, supply chain, and delivery operations utilizing AWS’s portfolio of cloud services. AWS’ AI & ML services help Novartis […]readmore
Shots: Eris Lifesciences acquired Novartis’ novel therapy Zomelis for $13M (~INR 93 crore) and will initiate the commercialization of product from Dec 10, 2019 in India The acquisition of Zomelis […]readmore
Shots: Novartis to acquire The Medicine Company in all-cash transaction for $85/share at a 24% 1-day premium, making fully diluted equity value as $7.7B and a total deal value as […]readmore
1. Lupin Launches Smart Device for Metered-Dose Inhalers to Support Treatment of Respiratory Diseases in India Published: Nov 22, 2019 | Tags: Lupin, Launches, Smart Device, Metered-Dose Inhalers, Support, Treatment, […]readmore
Shots: Novartis enters into a 3yrs. collaboration with MILA for transforming the discovery, development & commercialization of therapies by leveraging AI. The collaboration will lead to expansion of the pharmaceutical […]readmore
Shots: Novartis will access Biofourmis’ lead digital therapeutics, BiovitalsHF to manage patients with heart failure across Asia, with a potential plan to expand it globally The focus of the collaboration […]readmore